Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial
Rubhana Raqib,Protim Sarker,Akhirunnesa Mily,Nur H. Alam,Abu Saleh Mohammed Arifuzzaman,Rokeya Sultana Rekha,Jan Andersson,Gudmundur H. Gudmundsson,Alejandro Cravioto,Birgitta Agerberth +9 more
Reads0
Chats0
TLDR
Adjunct therapy with butyrate during shigellosis led to early reduction of inflammation and enhanced LL-37 expression in the rectal epithelia with prolonged release of LL-36 in the stool and improvement in rectal histopathology.Abstract:
Treatment of shigellosis in rabbits with butyrate reduces clinical severity and counteracts the downregulation of cathelicidin (CAP-18) in the large intestinal epithelia Here, we aimed to evaluate whether butyrate can be used as an adjunct to antibiotics in the treatment of shigellosis in patients A randomized, double-blind, placebo-controlled, parallel-group designed clinical trial was conducted Eighty adult patients with shigellosis were randomized to either the Intervention group (butyrate, n = 40) or the Placebo group (normal saline, n = 40) The Intervention group was given an enema containing sodium butyrate (80 mM), twice daily for 3 days, while the Placebo group received the same dose of normal saline The primary endpoint of the trial was to assess the efficacy of butyrate in improving clinical, endoscopic and histological features of shigellosis The secondary endpoint was to study the effect of butyrate on the induction of antimicrobial peptides in the rectum Clinical outcomes were assessed and concentrations of antimicrobial peptides (LL-37, human beta defensin1 [HBD-1] and human beta defensin 3 [HBD-3]) and pro-inflammatory cytokines (interleukin-1β [IL-1β] and interleukin-8 [IL-8]) were measured in the stool Sigmoidoscopic and histopathological analyses, and immunostaining of LL-37 in the rectal mucosa were performed in a subgroup of patients Compared with placebo, butyrate therapy led to the early reduction of macrophages, pus cells, IL-8 and IL-1β in the stool and improvement in rectal histopathology Butyrate treatment induced LL-37 expression in the rectal epithelia Stool concentration of LL-37 remained significantly higher in the Intervention group on days 4 and 7 Adjunct therapy with butyrate during shigellosis led to early reduction of inflammation and enhanced LL-37 expression in the rectal epithelia with prolonged release of LL-37 in the stool ClinicalTrialsgov, NCT00800930read more
Citations
More filters
Journal ArticleDOI
Regulation of immune cell function by short-chain fatty acids
Renan Corrêa-Oliveira,José Luís Fachi,Aline Vieira,Fabio Takeo Sato,Marco Aurélio Ramirez Vinolo +4 more
TL;DR: The aim of this review is to present a clear and updated description of the effects of the SCFAs derived from bacteria on host immune system, as well as the molecular mechanisms involved on them.
Journal ArticleDOI
Role of intestinal microbiota and metabolites on gut homeostasis and human diseases
Lan Lin,Jianqiong Zhang +1 more
TL;DR: A better understanding of the mutual interactions of the microbiota and host immune system, would shed light on the endeavors of disease prevention and broaden the path to the discovery of immune intervention targets for disease treatment.
Book ChapterDOI
Regulation of Bacterial Pathogenesis by Intestinal Short-Chain Fatty Acids
Yvonne Sun,Mary X. D. O'Riordan +1 more
TL;DR: The biological role of short-chain fatty acids (SCFA), which are fermentation end products of the intestinal microbiota, in host-pathogen interactions, are dissected to highlight the importance of the chemical environment where the biology of the host, the microbiota, and the pathogen intersects, which provides a basis for designing effective infection prevention and control.
Journal ArticleDOI
Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection
Quinten R Ducarmon,Romy D. Zwittink,Bastian V. H. Hornung,W. van Schaik,Vincent B. Young,E.J. Kuijper +5 more
TL;DR: Current knowledge on how the gut microbiota can mediate colonization resistance against bacterial enteric infection and on how bacterial enteropathogens can overcome this resistance are summarized.
Journal ArticleDOI
Butyrate Protects Mice from Clostridium difficile-Induced Colitis through an HIF-1-Dependent Mechanism.
José Luís Fachi,Jaqueline de Souza Felipe,Laís Passariello Pral,Bruna Karadi da Silva,Renan O. Corrêa,Mirella Cristiny Pereira de Andrade,Denise Morais da Fonseca,Paulo José Basso,Niels Olsen Saraiva Câmara,Éricka Lorenna de Sales e Souza,Flaviano S. Martins,Suzana Eiko Sato Guima,Andrew Maltez Thomas,João C. Setubal,João C. Setubal,Yuli Thamires Magalhães,Fabio Luis Forti,Thamiris Candreva,Hosana G. Rodrigues,Marcelo Bispo de Jesus,Sílvio Roberto Consonni,Alessandro S. Farias,Patrick Varga-Weisz,Patrick Varga-Weisz,Marco Aurélio Ramirez Vinolo +24 more
TL;DR: It is concluded that butyrate protects intestinal epithelial cells from damage caused by C. difficile-induced colitis via the stabilization of HIF-1, mitigating local inflammatory response and systemic consequences of the infection.
References
More filters
Journal ArticleDOI
Antimicrobial peptides of multicellular organisms
TL;DR: As the need for new antibiotics becomes more pressing, could the design of anti-infective drugs based on the design principles these molecules teach us?
Journal ArticleDOI
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
Kendle M. Maslowski,Angélica T. Vieira,Angélica T. Vieira,Aylwin Ng,Jan Kranich,Frederic Sierro,Di Yu,Heidi C. Schilter,Heidi C. Schilter,Michael S. Rolph,Fabienne Mackay,Fabienne Mackay,David Artis,Ramnik J. Xavier,Ramnik J. Xavier,Mauro M. Teixeira,Charles R. Mackay +16 more
TL;DR: It is shown that SCFA–GPR43 interactions profoundly affect inflammatory responses, and GPR43 binding of SCFAs potentially provides a molecular link between diet, gastrointestinal bacterial metabolism, and immune and inflammatory responses.
Journal ArticleDOI
Review article: the role of butyrate on colonic function
Henrike M. Hamer,Daisy Jonkers,Koen Venema,Steven Vanhoutvin,Freddy J. Troost,Robert Brummer +5 more
TL;DR: Butyrate is an important energy source for intestinal epithelial cells and plays a role in the maintenance of colonic homeostasis, and is a main end‐product of intestinal microbial fermentation of mainly dietary fibre.
Journal ArticleDOI
Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease
Jean-Pierre Segain,D. Raingeard de la Blétière,Arnaud Bourreille,V. Leray,Nadine Gervois,Carlos Rosales,L Ferrier,C. Bonnet,Hervé M. Blottière,J. P. Galmiche +9 more
TL;DR: Butyrate decreases proinflammatory cytokine expression via inhibition of NFκB activation and IκBα degradation and these anti-inflammatory properties provide a rationale for assessing butyrate in the treatment of CD.
Journal ArticleDOI
Potential beneficial effects of butyrate in intestinal and extraintestinal diseases
Roberto Berni Canani,Margherita Di Costanzo,Ludovica Leone,Monica Pedata,Rosaria Meli,Antonio Calignano +5 more
TL;DR: A wide spectrum of positive effects exerted by butyrate is suggested, with a high potential for a therapeutic use in human medicine, at the extraintestinal and intestinal level.